18F-fluorothymidine-pet imaging of glioblastoma multiforme: Effects of radiation therapy on radiotracer uptake and molecular biomarker patterns

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Chandrasekaran, Sanjay ^a   Hollander, Andrew ^b   Xu, Xiangsheng ^b   Benci, Joseph L ^b   Davis, James J ^b   Dorsey, Jay F ^b   Kao, Gary ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; HISTONE GAMMA H2AX; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; THYMIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLUCOSE TRANSPORT; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SIGNAL NOISE RATIO; ANIMAL; BRAIN; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; RADIATION DOSE; RADIATION EXPOSURE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; FEMALE; GLIOBLASTOMA; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84877304807     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/796029     Document Type: Article

References (48)

1. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R. O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology 2009 10 5 459 466 2-s2.0-65349121788 10.1016/S1470-2045(09)70025-7
2. Borbely K., Wintermark M., Martos J., Fedorcsak I., Bognar L., Kasler M., The pre-requisite of a second-generation glioma PET biomarker. Journal of the Neurological Sciences 2010 298 1-2 11 16 2-s2.0-77958152580 10.1016/j.jns.2010. 07.024
3. Saif M. W., Tzannou I., Makrilia N., Syrigos K., Role and cost effectiveness of PET/CT in management of patients with cancer. Yale Journal of Biology and Medicine 2010 83 2 53 65 2-s2.0-77957345709
4. Padma M. V., Said S., Jacobs M., Hwang D. R., Dunigan K., Satter M., Christian B., Ruppert J., Bernstein T., Kraus G., Mantil J. C., Prediction of pathology and survival by FDG PET in gliomas. Journal of Neuro-Oncology 2003 64 3 227 237 2-s2.0-0141794250 10.1023/A:1025665820001 (Pubitemid 37203463)
5. Di Chiro G., Brooks R. A., Patronas N. J., Bairamian D., Kornblith P. L., Smith B. H., Mansi L., Barker J., Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Annals of Neurology 1984 supplement 15 S138 S146 (Pubitemid 14138676)
6. Nanni C., Fantini L., Nicolini S., Fanti S., Non FDG PET. Clinical Radiology 2010 65 7 536 548 2-s2.0-77953302964 10.1016/j.crad.2010.03.012
7. 18F- fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. Journal of Neuro-Oncology 2007 84 3 305 314 2-s2.0-35448942790 10.1007/s11060-007-9375-6
8. 18F- fluorothymidine (FLT) positron emission tomography in recurrent high-grade gliomas, differentiation from treatment-induced tissue necrosis. Cancers 2012 4 1 244 256
9. Spence A. M., Muzi M., Link J. M., Hoffman J. M., Eary J. F., Krohn K. A., NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety Studies. Molecular Imaging and Biology 2008 10 5 271 280 2-s2.0-49149108259 10.1007/s11307-008-0151-6
10. 18F-Fluorothymidine. Seminars in Nuclear Medicine 2007 37 6 429 439 2-s2.0-34848881062 10.1053/j.semnuclmed.2007.08.001 (Pubitemid 47498262)
11. Rasey J. S., Grierson J. R., Wiens L. W., Kolb P. D., Schwartz J. L., Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. Journal of Nuclear Medicine 2002 43 9 1210 1217 2-s2.0-0036732034 (Pubitemid 34988769)
12. 18F-fluorothymidine in patients with gliomas. Journal of Nuclear 2006 47 10 1612 1621 (Pubitemid 47545026)
13. 18F-FDG. Journal of Nuclear Medicine 2005 46 6 945 952 2-s2.0-23044460494 (Pubitemid 43733508)
14. Ullrich R., Backes H., Li H., Kracht L., Miletic H., Kesper K., Neumaier B., Heiss W. D., Wienhard K., Jacobs A. H., Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L- thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clinical Cancer Research 2008 14 7 2049 2055 2-s2.0-42249098076 10.1158/1078-0432.CCR-07-1553 (Pubitemid 351551115)
15. 18F- fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomsas: Preliminary Efficacy Studies. Molecular Imaging and Biology 2009 11 5 343 355 2-s2.0-68449095057 10.1007/s11307-009-0215-2
16. 18F-fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Research 2005 65 21 10104 10112 2-s2.0-27544449023 10.1158/0008-5472.CAN-04-4297 (Pubitemid 41541493)
17. 18F-fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clinical Cancer Research 2007 13 12 3552 3558 2-s2.0-34250721718 10.1158/1078-0432.CCR-06-3025 (Pubitemid 46955115)
18. 18F- 3′ -fluoro- 3′ -deoxy-L-thymidine. Clinical Cancer Research 2004 10 5 1685 1690 2-s2.0-1842481203 10.1158/1078-0432.CCR-03-0040 (Pubitemid 38435559)
19. 18F-FLT-PET in oncology: current status and opportunities. European Journal of Nuclear Medicine and Molecular Imaging 2004 31 12 1659 1672 2-s2.0-12144281203 10.1007/s00259-004-1687-6 (Pubitemid 40104613)
20. Morton C. L., Houghton P. J., Establishment of human tumor xenografts in immunodeficient mice. Nature Protocols 2007 2 2 247 250 (Pubitemid 47040037)
21. Baumann B., Benji J., Santoiemma P., Chandrasekaran S., Hollander A., Kao G., Dorsey J., An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation. Translational Oncology 2012 5 4 230 237
22. Bryant M. J., Chuah T. L., Luff J., Lavin M. F., Walker D. G., A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. Journal of Clinical Neuroscience 2008 15 5 545 551 2-s2.0-41549132494 10.1016/j.jocn.2007.04.022
23. Brat D. J., Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Research 2004 64 3 920 927 (Pubitemid 38176893)
24. Jensen R. L., Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. Journal of Neuro-Oncology 2009 92 3 317 335 2-s2.0-65249131228 10.1007/s11060-009-9827-2
25. van der Linden Y. M., Steenland E., van Houwelingen H. C., Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiotherapy and Oncology 2006 78 3 245 253 2-s2.0-33645986651 10.1016/j.radonc.2006.02.007
26. Steenland E., Leer J., Van Houwelingen H., Post W. J., Van den Hout W. B., Kievit J., De Haes H., Martijn H., Oei B., Vonk E., Van der Steen-Banasik E., Wiggenraad R. G. J., Hoogenhout J., Wárlám-Rodenhuis C., Van Tienhoven G., Wanders R., Pomp J., Van Reijn M., Van Mierlo T., Rutten E., The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiotherapy and Oncology 1999 52 2 101 109 2-s2.0-0033179896 10.1016/S0167-8140(99)00110-3 (Pubitemid 29461077)
27. Henson J. W., Hobbs W., Chakravarti A., Louis D. N., Alterations in p53, p21, and MIB-1 labeling index in primary human astrocytomas following radiation therapy. Journal of Neuro-Oncology 2005 74 2 151 154 2-s2.0-26944436979 10.1007/s11060-004-6911-5 (Pubitemid 41478910)
28. Valente G., Orecchia R., Gandolfo S., Arnaudo M., Ragona R., Kerim S., Palestro G., Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? Journal of Clinical Pathology 1994 47 2 109 112 2-s2.0-0028353328 (Pubitemid 24095460)
29. Rogakou E. P., Pilch D. R., Orr A. H., Ivanova V. S., Bonner W. M., DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. Journal of Biological Chemistry 1998 273 10 5858 5868 2-s2.0-0032489520 10.1074/jbc.273.10.5858 (Pubitemid 28124064)
30. Sak A., Stuschke M., Use of γ H2AX and other biomarkers of double-strand breaks during radiotherapy. Seminars in Radiation Oncology 2010 20 4 223 231 2-s2.0-77956460186 10.1016/j.semradonc.2010.05.004
31. Olive P. L., Banath J. P., Phosphorylation of histone H2AX as a measure of radiosensitivity. International Journal of Radiation Oncology, Biology, Physics 2004 58 2 331 335 (Pubitemid 38142456)
32. Paulus W., Peiffer J., Intratumoral histologic heterogeneity of gliomas: A Quantitative Study. Cancer 1989 64 2 442 447 2-s2.0-0024348833 (Pubitemid 19180407)
33. Hoelzinger D. B., Mariani L., Wies J., Woyke T., Berens T. J., McDonough W. S., Sloan A., Coons S. W., Berens M. E., Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005 7 1 7 16 2-s2.0-13444294190 10.1593/neo.04535 (Pubitemid 40209466)
34. Raza S. M., Lang F. F., Aggarwal B. B., Fuller G. N., Wildrick D. M., Sawaya R., Rutka J. T., Piepmeier J. M., Warnke P. C., Glick R. P., Lichtor T., Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002 51 1 2 13 2-s2.0-0036664779 10.1097/00006123-200207000-00002 (Pubitemid 36331094)
35. Lu C., Zhu F., Cho Y. Y., Tang F., Zykova T., Ma W. Y., Bode A. M., Dong Z., Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Molecular Cell 2006 23 1 121 132 2-s2.0-33745487368 10.1016/j.molcel.2006.05.023 (Pubitemid 43963445)
36. Lu C., Shi Y., Wang Z., Song Z., Zhu M., Cai Q., Chen T., Serum starvation induces H2AX phosphorylation to regulate apoptosis via p38 MAPK pathway. FEBS Letters 2008 582 18 2703 2708 2-s2.0-47849120976 10.1016/j.febslet.2008.06.051
37. Sluss H. K., Davis R. J., H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Molecular Cell 2006 23 2 152 153 2-s2.0-33745934311 10.1016/j.molcel.2006.07.001 (Pubitemid 44062374)
38. 18F-fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clinical Cancer Research 2008 14 9 2623 2630
39. Kaur B., Khwaja F. W., Severson E. A., Matheny S. L., Brat D. J., Van Meir E. G., Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology 2005 7 2 134 153 2-s2.0-17844371306 10.1215/S1152851704001115 (Pubitemid 40590514)
40. Ferrara N., Davis-Smyth T., The biology of vascular endothelial growth factor. Endocrine Reviews 1997 18 1 4 25 (Pubitemid 27076453)
41. Ferrara N., Keyt B., Vascular endothelial growth factor: basic biology and clinical implications. EXS 1997 79 209 232 2-s2.0-0030635918
42. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
43. Kaur B., Tan C., Brat D. J., Van Meir E. G., Genetic and hypoxic regulation of angiogenesis in gliomas. Journal of Neuro-Oncology 2004 70 2 229 243 2-s2.0-9144247005 10.1007/s11060-004-2752-5 (Pubitemid 39545734)
44. Jiang Y. G., Peng Y., Koussougbo K. S., Necroptosis: a novel therapeutic target for glioblastoma. Medical Hypotheses 2011 76 3 350 352 2-s2.0-79751524886 10.1016/j.mehy.2010.10.037
45. Jong K. W., Tofilon P. J., Camphausen K., Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiation Oncology 2012 7 1 25
46. Moeller B. J., Cao Y., Li C. Y., Dewhirst M. W., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004 5 5 429 441 2-s2.0-2342611976 10.1016/S1535-6108(04)00115-1 (Pubitemid 38610245)
47. Dewhirst M. W., Cao Y., Li C. Y., Moeller B., Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiotherapy and Oncology 2007 83 3 249 255 2-s2.0-34250219672 10.1016/j.radonc.2007.05.016 (Pubitemid 46907988)
48. Schwartz D. L., Powis G., Thitai-Kumar A., He Y., Bankson J., Williams R., Lemos R., Oh J., Volgin A., Soghomonyan S., Nishii R., Alauddin M., Mukhopadhay U., Peng Z., Bornmann W., Gelovani J., The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics 2009 8 4 947 958 2-s2.0-66449118481 10.1158/1535-7163.MCT-08-0981